novocure(NVCR)2025-02-27 12:02Financial Performance - Preliminary full year 2024 net revenues were $605.2 million, a 19% increase compared to the prior year[3] - Fourth quarter net revenues totaled $161.3 million, reflecting a 21% increase year-over-year[3] - The U.S., Germany, France, and Japan contributed $107.2 million, $17.7 million, $16.0 million, and $8.5 million to fourth quarter revenues, respectively[3] Patient and Treatment Updates - As of December 31, 2024, there were 4,126 total active patients on TTFields therapy globally[7] - 1,520 Optune Gio prescriptions were received in the fourth quarter, consistent with the same period in 2023[7] - As of December 31, 2024, there were 20 active NSCLC patients on Optune Lua[7] Regulatory Approvals and Designations - Optune Lua was approved by the FDA for the treatment of metastatic non-small cell lung cancer on October 15, 2024[7] - The FDA granted Breakthrough Device designation for TTFields therapy for brain metastases from non-small cell lung cancer in October 2024[7] Financial Position - Cash, cash equivalents, and short-term investments were $959.9 million as of December 31, 2024[7] Clinical Trials - Novocure plans to submit full data from the Phase 3 PANOVA-3 clinical trial for pancreatic cancer at an upcoming medical congress[13]